Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted

Ninety-seven percent of care partners reported that agitation negatively impacted their loved one’s quality of life, and three in four wish they had recognized symptoms sooner

Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana

Survey conducted by The Harris Poll and in collaboration with CaringKind

NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer’s Day, announced results of the Shared Goals: Navigating Alzheimer’s Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer’s disease and their family care partners.

A welcome email is on its way. If you don't see it, please check your junk folder.

The Shared Goals survey of 751 adults who currently provide care to a loved one with Alzheimer’s disease was conducted online by The Harris Poll, with input from CaringKind, a leading expert on Alzheimer’s and dementia caregiving with over 40 years of experience, and sponsored by Axsome. It is among the largest and most recent surveys of care partners of people living with Alzheimer’s disease agitation. The Shared Goals survey results were presented at Psych Congress 2026 in New Orleans, Louisiana, on September 17 and 18, 2026.

“These survey findings give important insights into why there is such a delay in recognition of symptoms of agitation. Because the behaviors doing the most damage can be mistaken for personality changes or disease progression, they often go unaddressed until daily life is significantly disrupted,” said Brent P. Forester, M.D., psychiatrist-in-chief and chair of the Department of Psychiatry at Tufts Medical Center and director of Behavioral Health for Tufts Medicine. “Recognizing these behaviors early and discussing them with a healthcare provider allows families and clinicians to set shared goals for care and discuss treatment options, which may help them manage agitation before it becomes too overwhelming to them.”

Care partners surveyed reported that agitation negatively affected their loved one’s overall quality of life (97%), ability to care for themselves (96%), community engagement (95%) and maintaining relationships with family and friends (89%).